Dr. Henry is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3350 La Jolla Village Dr
111g
San Diego, CA 92161Phone+1 858-642-3648Fax+1 858-642-6242
Education & Training
- University of ManitobaClass of 1975
Certifications & Licensure
- CA State Medical License 1984 - 2020
Clinical Trials
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes Start of enrollment: 2013 May 01
Publications & Presentations
PubMed
- 7 citationsAstaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia.Theodore P Ciaraldi, Schafer C Boeder, Sunder R Mudaliar, Erin R Giovannetti, Robert R Henry
Diabetes, Obesity & Metabolism. 2023-07-01 - 2 citationsAdipose tissue from subjects with type 2 diabetes exhibits impaired capillary formation in response to GROα: involvement of MMPs-2 and -9.Yifat Amir Levy, Theodore P Ciaraldi, Sunder R Mudaliar, Susan A Phillips, Robert R Henry
Adipocyte. 2022-12-01 - 6 citationsp300 or CBP is required for insulin-stimulated glucose uptake in skeletal muscle and adipocytesVitor F. Martins, Samuel LaBarge, Alexandra Stanley, Kristoffer Svensson, Chao-Wei Hung
JCI Insight. 2021-11-23
Journal Articles
- Correction to: Mitochondrial H+-ATP Synthase in Human Skeletal Muscle: Contribution to Dyslipidaemia and Insulin ResistancePam Taub, Robert R Henry, Diabetologia
Press Mentions
- Elcelyx Therapeutics Reports Positive Results in Phase 2b Study of Metformin Delayed Release in Type 2 DiabetesNovember 11th, 2016
- American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of Sglt-2 Inhibitors and Diabetic KetoacidosisApril 16th, 2016
- REMD Biotherapeutics Announces Dosing of First Type 1 Diabetes Patient with REMD-477, a Glucagon Receptor Monoclonal AntibodyApril 6th, 2016
- Join now to see all
Committees
- member, AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN 2015
- member, 2011 AACE Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan
- member, American Association of Clinical Endocrinologists and American College of Endocrinology - Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan 2015
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: